Our Science

ex marks the spot.
ai cracks the code.

The future of early cancer detection starts with RNA.

Our next-generation RNA-based platform delivers actionable insight into cancer biology from a simple blood draw.

Our Performance

making our mark.

High accuracy and sensitivity.

Exai’s research demonstrates the potential of oncRNAs for early detection of cancer.

>85% sensitivity

DCIS (ductal carcinoma in situ)

>85% sensitivity

stage 1 breast cancer

>75% sensitivity

DCIS (ductal carcinoma in situ)

>85% sensitivity

stage 1 breast cancer

>90% sensitivity

stage I non-small cell lung cancer

>85% sensitivity

stage I across eight cancers

>90% sensitivity

stage I non-small cell lung cancer

>80% sensitivity

stage I breast cancer

>90% sensitivity

stage I colorectal cancer

predicting tissue-of-origin